Security Snapshot

Indivior Pharmaceuticals Inc - COMMON STOCK (ASRT) Institutional Ownership

CUSIP: 04546C106

13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

$30.48

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

SEC-reported price per share
$30.48
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ASRT - Indivior Pharmaceuticals Inc - COMMON STOCK is tracked under CUSIP 04546C106.
  • 13F reference-period holder data is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder data for the Q2 2026 reference period is not available.
  • Available periods remain in the history table; they do not substitute for the headline period.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

04546C106

13F reference period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
12
Headline period
n/a
Rows shown
1-12 of 12
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 6,984,102 $212,875,429 +$212,875,429 $30.48 1
2024 Q3 0 $0 -$2,048 $30.48 0
2024 Q2 3,000 $2,048 +$2,048 $0.68 1
2022 Q2 0 $0 -$1,054,000 $30.48 0
2022 Q1 367,100 $1,054,000 +$17,227 $2.87 1
2021 Q4 361,100 $787,000 +$309,245 $2.18 1
2021 Q3 220,500 $199,000 +$107,486 $0.74 2
2021 Q2 101,750 $158,000 -$26,715,055 $1.35 2
2021 Q1 39,131,456 $26,701,055 +$1,063,966 $0.68 53
2020 Q4 37,659,059 $13,461,000 -$5,302,012 $0.36 50
2020 Q3 46,810,126 $31,192,000 -$3,347,736 $0.67 61
2020 Q2 51,162,092 $43,844,000 +$43,844,000 $0.86 71
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .